MY164728A - Treatment of bone marrow edema (oedema) with polysulfated polysaccharides - Google Patents

Treatment of bone marrow edema (oedema) with polysulfated polysaccharides

Info

Publication number
MY164728A
MY164728A MYPI2013701355A MYPI2013701355A MY164728A MY 164728 A MY164728 A MY 164728A MY PI2013701355 A MYPI2013701355 A MY PI2013701355A MY PI2013701355 A MYPI2013701355 A MY PI2013701355A MY 164728 A MY164728 A MY 164728A
Authority
MY
Malaysia
Prior art keywords
treatment
bone marrow
oedema
marrow edema
polysulfated polysaccharides
Prior art date
Application number
MYPI2013701355A
Other languages
English (en)
Inventor
Peter Ghosh
Original Assignee
Paradigm Health Sciences Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011900325A external-priority patent/AU2011900325A0/en
Application filed by Paradigm Health Sciences Pty Ltd filed Critical Paradigm Health Sciences Pty Ltd
Publication of MY164728A publication Critical patent/MY164728A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI2013701355A 2011-02-02 2012-02-02 Treatment of bone marrow edema (oedema) with polysulfated polysaccharides MY164728A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2011900325A AU2011900325A0 (en) 2011-02-02 Treatment of bone marrow edema (oedema) with polysulfated polysaccharides

Publications (1)

Publication Number Publication Date
MY164728A true MY164728A (en) 2018-01-30

Family

ID=46602012

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013701355A MY164728A (en) 2011-02-02 2012-02-02 Treatment of bone marrow edema (oedema) with polysulfated polysaccharides

Country Status (15)

Country Link
US (6) US9101650B2 (https=)
EP (1) EP2670412B1 (https=)
JP (1) JP5883458B2 (https=)
KR (1) KR101840079B1 (https=)
CN (1) CN103415293B (https=)
AU (1) AU2012212398B2 (https=)
CA (1) CA2826166C (https=)
DK (1) DK2670412T3 (https=)
ES (1) ES2664611T3 (https=)
MY (1) MY164728A (https=)
NO (1) NO2670412T3 (https=)
PT (1) PT2670412T (https=)
SG (1) SG192238A1 (https=)
TW (1) TWI520740B (https=)
WO (1) WO2012103588A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10098906B2 (en) * 2013-10-22 2018-10-16 Cell Receptor AG Modulation of the physical interaction between platelets and the cell surface effecting cell proliferation
CN111417399A (zh) * 2017-08-04 2020-07-14 帕拉迪生物制药有限公司 多硫酸化多糖治疗骨髓病变
WO2019157560A1 (en) 2018-02-16 2019-08-22 Proteobioactives Pty Limited Methods and compositions for the treatment of pain and/or inflammation
JP7391858B2 (ja) * 2018-02-28 2023-12-05 パラダイム バイオファーマシューティカルズ リミテッド ポリ硫酸化多糖類を用いた術後関節痛の処置
FI3863647T3 (fi) * 2018-10-10 2024-03-01 Paradigm Biopharmaceuticals Ltd Pahanlaatuisen luustokivun hoitaminen pentosaanipolysulfaatilla

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668116A (en) 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
US6593310B1 (en) 2000-11-21 2003-07-15 Arthropharm Pty. Ltd. Treatment of osteoporosis
US6564083B2 (en) * 2000-12-18 2003-05-13 Hoffmann-La Roche Inc. Bone marrow edema as predictive of susceptibility to developing progressive osteoarthritis
DE10225551A1 (de) * 2002-06-06 2003-12-24 Schering Ag Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind
KR101718375B1 (ko) 2007-12-04 2017-03-22 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절

Also Published As

Publication number Publication date
EP2670412A4 (en) 2015-07-08
AU2012212398B2 (en) 2014-06-05
CN103415293B (zh) 2016-08-10
CA2826166A1 (en) 2012-08-09
US20150297633A1 (en) 2015-10-22
KR20140012655A (ko) 2014-02-03
KR101840079B1 (ko) 2018-03-19
CA2826166C (en) 2017-05-09
SG192238A1 (en) 2013-09-30
EP2670412B1 (en) 2018-01-03
US10610542B2 (en) 2020-04-07
WO2012103588A1 (en) 2012-08-09
US20140024614A1 (en) 2014-01-23
US20240156858A1 (en) 2024-05-16
US20210015849A1 (en) 2021-01-21
US20180021369A1 (en) 2018-01-25
TW201309307A (zh) 2013-03-01
US20220362284A1 (en) 2022-11-17
JP2014504613A (ja) 2014-02-24
PT2670412T (pt) 2018-03-20
JP5883458B2 (ja) 2016-03-15
DK2670412T3 (en) 2018-03-12
US11406660B2 (en) 2022-08-09
CN103415293A (zh) 2013-11-27
US9861657B2 (en) 2018-01-09
TWI520740B (zh) 2016-02-11
US9101650B2 (en) 2015-08-11
EP2670412A1 (en) 2013-12-11
NO2670412T3 (https=) 2018-06-02
AU2012212398A1 (en) 2013-09-19
ES2664611T3 (es) 2018-04-20

Similar Documents

Publication Publication Date Title
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
MY163341A (en) Carbohydrate based binder system and method of its production
PH12013502144A1 (en) Multiple myeloma treatment
MX2015010191A (es) Metodos para tratar infecciones microbianas, incluyendo mastitis.
MX2016008226A (es) Metodos para el cuidado oral prebiotico usando un sacarido.
IN2014CN04634A (https=)
MX364220B (es) Metodos de tratamientos de fibrosis.
IN2014MN00908A (https=)
WO2014153009A3 (en) Thiosaccharide mucolytic agents
MX2014005398A (es) Metodos para tratar ataques de gota.
MX343059B (es) Derivados de desmetil-estradiol sustituido en 6 como agonistas de er-beta selectivos.
GB2525835A (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
IN2014DN07958A (https=)
MY164728A (en) Treatment of bone marrow edema (oedema) with polysulfated polysaccharides
BR112015028325A2 (pt) processo para fabricar lítio carboximetil celulose
MY173722A (en) Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome
MX2019012659A (es) Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido.
AU2012240388A8 (en) Treatment regimens
MX2012012978A (es) Metodo para producir pleurodesis.
MX2016002638A (es) Formulas de rehidratacion oral con prebioticos galactooligosacaridos.
PH12014500973A1 (en) Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
NZ717880A (en) Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors
WO2013090319A3 (en) Treatment of type i and type ii diabetes
MX2012008317A (es) Uso prebiotico de polisacarido de soja soluble en agua.